CRO prices increasing, survey finds

By Nick Taylor

- Last updated on GMT

Related tags Pharmacology

Survey results have again surprised analysts by showing prices charged by CROs, particularly to large pharma, have increased in recent months.

Volume-based discounts and overcapacity are believed to be depressing prices charged by contract research organisations (CROs). However, for the second time this year​ more than a third of surveyed biopharm employees said outsourcing prices are increasing.

We felt like our [first half of 2011] data might have been an anomaly and we provided multiple caveats. However, [second half of 2011] survey results are even more supportive​”, Eric Coldwell, equity analyst at RW Baird, said.

In the latest survey 42% of respondents said pricing has increased over the past three months, up from one-third in the earlier report. The proportion of staff at mid-sized and large pharma reporting price increases jumped to close to half in the latest survey, offsetting a dip among smaller firms.

Increases were reported by more than half of clinically focused respondents, compared to around one-quarter of those working in preclinical. Decreases were equally rare in both groups. Small firms and European-based biopharm reported more decreases than other groups.

The ratio of respondents reporting price increases to decreases was 6:1, compared to 5:1 in the April survey. Reported price increases averaged at mid-to-upper single digits.

Why, why, why?

The reason the survey found price increases, which goes against what CROs have reported, is unclear. “Last report we suggested that one of the drivers of the unexpectedly strong pricing data might relate to those working specifically in fields where capacity has come out​”, Coldwell said.

Phase I capacity has been cut and this could quickly lead to price increases. Coldwell said: “If one of two Phase I sites in a market closes we would expect the remaining site to have substantially better recruiting capabilities and for capacity to fill, and prices to increase, fairly rapidly​.”

Of the 12 respondents working in clinical pharmacology, 11 said prices have increased. The other group that overwhelmingly reported price increases was Asia-Pacific-based biopharm. Rising labour costs in emerging markets, such as China, could account for the increase in their outsourcing prices.

While we still have much to learn about this survey feedback,one thing is certain: the vast majority of internal pharma staff surveyed believe that they are spending the same, or more, per unit of outsourced work today than in the recent past​”, Coldwell said.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more